Walsh & Associates’s Merck MRK Stock Holding History

Walsh & Associates’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4	Closed	-$481	–	274
2026 Q1	$481	Buy	+4	New	+$462	﹤0.01%	233

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Walsh & Associates's MRK Position: Q2 2026 in Review

Walsh & Associates sold out of Merck (MRK) in Q2 2026, closing a stake of 4 shares — an estimated $481 sold.

Walsh & Associates first reported a position in MRK in Q1 2026 and held it in 1 quarter. The position peaked at $481 in Q1 2026. 3,813 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Walsh & Associates reported no remaining Merck position as of Q2 2026 after selling out during the quarter.
Walsh & Associates sold 4 Merck shares in Q2 2026, an estimated $481.
Walsh & Associates first reported a position in Merck in Q1 2026 and held it in 1 quarter.
Walsh & Associates's Merck position peaked at $481 in Q1 2026.
3,813 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Walsh & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.